Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Debridement & negative-pressure wound therapy · New York | Debridement & negative-pressure wound therapy · New Jersey | |
|---|---|---|
| Surgeons, 2024 | 877 | 590 |
| Medicare fee-for-service cases | 165,137 | 129,243 |
| Growth since 2019 (Medicare FFS) | −3.1%/yr | −0.9%/yr |
| Forecast cases (Medicare FFS) | 176,500 in 2030 | 147,900 in 2030 |
| Forecast growth | +1.1%/yr to 2030 | +2.3%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 86.3 | 118.7 |
| Medicare Advantage share | 57% | 45% |
| Out of hospital | 54% (−5 pts since 2019) | 49% (−4 pts since 2019) |
| Cases per surgeon | 188 | 219 |
| Top 10 surgeons' share | 19% | 14% |
| Surgeons growing | 183 | 145 |
| New since the base year | 266 | 187 |
| Likely to stop billing it | 185 by 2026 | 70 by 2026 |
| Forecast miss, 1 year (procedure) | 3% | 3% |
| Company payments per surgeon | $1,155 | $695 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.